🚨 News 🚨 The U.S. FDA has approved ustekinumab-hmny injection, a biosimilar referencing ustekinumab injection, for the treatment of conditions including moderate-to-severe plaque #psoriasis and active #PsoriaticArthritis. 👉 https://loom.ly/ISfxFlg #MedNews #MedEd
About us
The Psoriasis and Psoriatic Arthritis Hub (PsOPsA Hub) is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in psoriasis and psoriatic arthritis. Our aim is to enhance knowledge in psoriasis and psoriatic arthritis through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. The Psoriasis and Psoriatic Arthritis Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
- Website
-
https://psoriasis-hub.com/
External link for PsOPsA Hub
- Industry
- E-Learning Providers
- Company size
- 11-50 employees
- Type
- Privately Held
Employees at PsOPsA Hub
Updates
-
🚨 News 🚨 The U.S. FDA has approved roflumilast topical foam 0.3% for the treatment of plaque #psoriasis of the scalp and body in adults and adolescents aged ≥12 years. Read more: https://loom.ly/5DMCVOI #MedNews #MedEd
-
-
📝 A phase III study published in Jama Dermatology found that once-daily roflumilast foam 0.3% is effective and tolerable in adolescents and adults with scalp and body #psoriasis. More news: https://loom.ly/v7Cb87I #MedNews #MedEd
-
-
🚨 News 🚨 The U.S. FDA has expanded the interchangeable designation for adalimumab-aaty biosimilar to cover all marketed dosage forms and strengths of the reference product, adalimumab, for conditions including plaque #psoriasis and #PsoriaticArthritis. 👉 https://loom.ly/1G9cHjk #MedNews #MedEd
-
-
New publication 📝 Phase III ARRECTOR results published in Jama Dermatology show efficacy and tolerability of roflumilast foam 0.3% in adolescents and adults with scalp and body #psoriasis. Learn more: https://loom.ly/v7Cb87I #MedNews #MedEd
-
-
🚨 News 🚨 The U.S. FDA has designated ustekinumab-aauz biosimilar as interchangeable with its reference product, ustekinumab, for all its indications including moderate-to-severe plaque #psoriasis and active psoriatic arthritis. 👉 https://loom.ly/YDUUfus #MedNews #MedEd
-
-
📝 Results from a cross-sectional study published in Oxford Academic support PASDAS as a composite measure for skin involvement in PsA in clinical practice and clinical trials. More news: psoriasis-hub.com #psoriasis #MedNews #MedEd
-
-
New publication 📝 Results from a cross-sectional study published in Oxford Academic show that PASDAS, and physician and patient global VAS scores increased with worsening skin severity (p ≤ 0.001 each) in patients with PsA. Learn more: https://loom.ly/eO8g-Go #psoriasis #MedNews #MedEd
-
-
📝 A new study published in Psoriasis (Auckland) found that predictors of early super-response with bimekizumab treatment included lower baseline PASI, absence of nail involvement, and fewer prior biologic therapy failures. More news: https://psoriasis-hub.com/ #psoriasis #MedNews #MedEd
-
-
📝 A 3-year interim analysis published in Rheumatology International found that secukinumab-related AEs were experienced by 13.3% and 13.6% of patients in the PsA and ankylosing spondylitis cohorts, respectively. More news: psoriasis-hub.com #PsoriaticArthritis #MedNews #MedEd
-